Compile Data Set for Download or QSAR
Report error Found 7502 for UniProtKB: P36888
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM50300690(CHEMBL576982 | N-(5-tert-Butyl-isoxazol-3-yl)-N'-{...)
Affinity DataIC50: 0.00200nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM50300690(CHEMBL576982 | N-(5-tert-Butyl-isoxazol-3-yl)-N'-{...)
Affinity DataIC50: 0.00200nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM50377170(CHEMBL256570 | US11254667, Compound I-2 | US115422...)
Affinity DataIC50: 0.00900nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM139540(US8889696, Staurosporine | US9051313, Staurosporin...)
Affinity DataIC50: 0.00900nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM50377170(CHEMBL256570 | US11254667, Compound I-2 | US115422...)
Affinity DataIC50: 0.00900nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University

Curated by ChEMBL
LigandPNGBDBM50601440(CHEMBL5176837)
Affinity DataKd:  0.0100nMAssay Description:Binding affinity to FLT3-ITD-D835V mutant (unknown origin) assessed as dissociation constantMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2023
Entry Details
PubMed
TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538621(NCGC 00371481 | US11254667, Compound I-24 | US1154...)
Affinity DataKd:  0.0100nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621115(US20230303563, Compound 117)
Affinity DataKd:  0.0110nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621098(6-(6-(difluorometh- oxy)imidazo[1,2-a]- pyridin-3-...)
Affinity DataKd:  0.0120nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621169(6-(6- (difluoromethyl)imidazo[1,2- a]pyridin-3-yl)...)
Affinity DataKd:  0.0140nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University

Curated by ChEMBL
LigandPNGBDBM50553656(CHEMBL4744130)
Affinity DataIC50: 0.0150nMAssay Description:Inhibition of FLT3 ITD mutant (unknown origin) expressed in mouse BaF3 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/25/2022
Entry Details Article
PubMed
TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University

Curated by ChEMBL
LigandPNGBDBM50593961(CHEMBL5195819)
Affinity DataKd:  0.0154nMAssay Description:Binding affinity to FLT3 ITD/F691L double mutant (unknown origin) by KINOMEscan assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM185149(Crenolanib | 1-[2-[5-[(3-methyloxetan-3-yl)methoxy...)
Affinity DataKd:  0.0160nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University

Curated by ChEMBL
LigandPNGBDBM621126(6-(6- (difluoromethyl)imidazo[1,2- a]pyridin-3-yl)...)
Affinity DataKd:  0.0170nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621166(N-((3S,4S)-4-fluoro- pyrrolidin-3-yl)-6-(6-(1- met...)
Affinity DataKd:  0.0200nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621126(6-(6- (difluoromethyl)imidazo[1,2- a]pyridin-3-yl)...)
Affinity DataKd:  0.0210nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538619(NCGC 00371479 | US11254667, Compound I-22 | US1154...)
Affinity DataKd:  0.0210nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621130(N-(6-(6- (difluoromethyl)imidazo[1,2- a]pyridin-3-...)
Affinity DataKd:  0.0230nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University

Curated by ChEMBL
LigandPNGBDBM50625571(CHEMBL5440655)
Affinity DataIC50: 0.0240nMAssay Description:Inhibition of FLT3 D835Y mutant (unknown origin)More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/18/2024
Entry Details
PubMed
TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University

Curated by ChEMBL
LigandPNGBDBM621115(US20230303563, Compound 117)
Affinity DataKd:  0.0240nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University

Curated by ChEMBL
LigandPNGBDBM622513(US20230312583, Compound I-9)
Affinity DataIC50: 0.0250nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University

Curated by ChEMBL
LigandPNGBDBM538621(NCGC 00371481 | US11254667, Compound I-24 | US1154...)
Affinity DataKd:  0.0250nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621123(US20230303563, Compound 165)
Affinity DataKd:  0.0250nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621165(Exemplary Synthetic Procedure #38 | US20230303563...)
Affinity DataKd:  0.0250nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University

Curated by ChEMBL
LigandPNGBDBM622509(US20230312583, Compound I-5)
Affinity DataIC50: 0.0250nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University

Curated by ChEMBL
LigandPNGBDBM622508(US20230312583, Compound I-4)
Affinity DataIC50: 0.0250nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University

Curated by ChEMBL
LigandPNGBDBM622511(US20230312583, Compound I-7)
Affinity DataIC50: 0.0250nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University

Curated by ChEMBL
LigandPNGBDBM621098(6-(6-(difluorometh- oxy)imidazo[1,2-a]- pyridin-3-...)
Affinity DataKd:  0.0290nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621168(6-(6-(1-cyclopropyl-1H- pyrazol-4-yl)imidazo- [1,2...)
Affinity DataKd:  0.0300nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University

Curated by ChEMBL
LigandPNGBDBM622512(US20230312583, Compound I-8)
Affinity DataIC50: 0.0310nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621117(2-(3-(6-(((3S,4S)-4- fluoropiperidin-3- yl)amino)p...)
Affinity DataKd:  0.0340nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University

Curated by ChEMBL
LigandPNGBDBM621169(6-(6- (difluoromethyl)imidazo[1,2- a]pyridin-3-yl)...)
Affinity DataKd:  0.0350nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [R834Q](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621126(6-(6- (difluoromethyl)imidazo[1,2- a]pyridin-3-yl)...)
Affinity DataKd:  0.0360nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835H](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621115(US20230303563, Compound 117)
Affinity DataKd:  0.0380nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University

Curated by ChEMBL
LigandPNGBDBM50533653(CHEMBL4519741)
Affinity DataIC50: 0.0380nMAssay Description:Inhibition of FLT3 ITD mutant (unknown origin) expressed in mouse BaF3 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/25/2022
Entry Details Article
PubMed
TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University

Curated by ChEMBL
LigandPNGBDBM50322535(3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-meth...)
Affinity DataIC50: 0.0400nMAssay Description:Inhibition of FLT3-ITD mutant (unknown origin) expressed in mouse BaF3 cells assessed as inhibition of FLT3-driven cell viability incubated for 72 hr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University

Curated by ChEMBL
LigandPNGBDBM50322535(3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-meth...)
Affinity DataIC50: 0.0400nMAssay Description:Inhibition of FLT3-ITD F691I mutant (unknown origin) expressed in mouse BaF3 cells assessed as inhibition of FLT3-driven cell viability incubated for...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621125((R)-N-(6-(6- (difluoromethyl)imidazo[1,2- a]pyridi...)
Affinity DataKd:  0.0410nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621098(6-(6-(difluorometh- oxy)imidazo[1,2-a]- pyridin-3-...)
Affinity DataKd:  0.0470nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621115(US20230303563, Compound 117)
Affinity DataKd:  0.0510nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621116(2-(3-(6-(((3S,4S)-4- fluoropyrrolidin-3- yl)amino)...)
Affinity DataKd:  0.0520nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621167(1-(4-(3-(6-(((3S,4S)-4- fluoropyrrolidin-3-yl)- am...)
Affinity DataKd:  0.0590nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University

Curated by ChEMBL
LigandPNGBDBM185149(Crenolanib | 1-[2-[5-[(3-methyloxetan-3-yl)methoxy...)
Affinity DataIC50: 0.0600nMAssay Description:Inhibition of FLT3 D835Y mutant (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University

Curated by ChEMBL
LigandPNGBDBM621130(N-(6-(6- (difluoromethyl)imidazo[1,2- a]pyridin-3-...)
Affinity DataKd:  0.0600nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University

Curated by ChEMBL
LigandPNGBDBM185149(Crenolanib | 1-[2-[5-[(3-methyloxetan-3-yl)methoxy...)
Affinity DataIC50: 0.0600nMAssay Description:Inhibition of FLT3 D835Y mutant (unknown origin) phosphorylation in mouse BaF3 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2024
Entry Details
PubMed
TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University

Curated by ChEMBL
LigandPNGBDBM50652366(CHEMBL5641673)
Affinity DataIC50: 0.0610nMAssay Description:Inhibition of recombinant FLT3 D835Y mutant (unknown origin) using peptide substrate incubated for for 30 mins by HTRF assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetReceptor-type tyrosine-protein kinase FLT3 [R834Q](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621115(US20230303563, Compound 117)
Affinity DataKd:  0.0610nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University

Curated by ChEMBL
LigandPNGBDBM50652349(CHEMBL5641913)
Affinity DataIC50: 0.0610nMAssay Description:Inhibition of recombinant wild type FLT3 kinase domain (unknown origin) using peptide substrate incubated for for 30 mins by HTRF assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621137(3,5-difluoro-N-((3S,4S)-4- fluoropiperidin-3-yl)-6...)
Affinity DataKd:  0.0620nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University

Curated by ChEMBL
LigandPNGBDBM50652354(CHEMBL5639694)
Affinity DataIC50: 0.0630nMAssay Description:Inhibition of recombinant wild type FLT3 kinase domain (unknown origin) using peptide substrate incubated for for 30 mins by HTRF assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
Displayed 1 to 50 (of 7502 total ) | Next | Last >>
Jump to: